Key result
Combining multiple RAAS blockers demonstrates an advantage over monotherapy in resistant hypertension, heart failure, and nephropathy, but fails to show benefit in high-risk cardiovascular patients.
Why the study?
Does combining multiple blockers of the renin-angiotensin-aldosterone system provide incremental benefit over monotherapy in specific patient populations?
Does combining multiple blockers of the renin-angiotensin-aldosterone system provide incremental benefit over monotherapy in specific patient populations?
Answers are grounded in this paper and cite their sources.
Combining multiple RAAS blockers may provide incremental benefits in specific populations like resistant hypertension and heart failure, but not in high-risk cardiovascular or post-MI patients.
Blockers of the renin–angiotensin–aldosterone system (RAAS) have an established role in the management of hypertension, cardiovascular and renal disorders. Since the RAAS can escape blockade from a drug with a single mechanism of action, it has been proposed that combining RAAS blockers with complementary mechanisms of action may provide incremental benefit. Studies utilizing various combinations of RAAS blockers have demonstrated an advantage over monotherapy in patients with resistant hypertension, heart failure and nephropathy, while failing to show benefit in patients at high risk of cardiovascular events (e.g., the ongoing Telmisartan Alone and in Combination with Ramipril Global End Point Trial) and in those after a myocardial infarction. In this article, we discuss the rationale for the use of multiple blockers of the renin–angiotensin system and the evidence for and against such an approach in particular patient populations by reviewing relevant clinical trials that have addressed this hypothesis.
No takes yet. Share an insight, caveat, or question.
Hage et al. (2011) conducted a review in Hypertension, cardiovascular and renal disorders. Multiple blockers of the renin-angiotensin-aldosterone system (RAAS) vs. Monotherapy was evaluated. Combining multiple RAAS blockers demonstrates an advantage over monotherapy in resistant hypertension, heart failure, and nephropathy, but fails to show benefit in high-risk cardiovascular patients.
Synapse has enriched 10 related papers. Consider them for comparative context: